Skip to main content
SpringerLink
Log in

Topical Analgesics for Neuropathic Pain in the Elderly: Current and Future Prospects

  • Leading Article
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Abstract

Neuropathic pain (NeP) is a significant medical and socioeconomic burden with limited therapeutic options. Elderly patients exhibit a higher incidence of several NeP conditions and pose a particular challenge due to age-related pharmacokinetic and pharmacodynamic issues, comorbid conditions, and polypharmacy, as well as frailty and cognitive decline. Topical analgesics are of interest because of their comparable efficacy to oral agents, good tolerability and safety, and potential to be add-on therapies to oral treatments. In recent years, two topical formulations for NeP have been approved (5 % lidocaine medicated plaster, 8 % capsaicin patch) but are not available in all countries. There are controlled trials and a growing body of open-label reports on their use in clinical care. Some studies provide a post hoc analysis of data in relation to older age (≥65 years), which is useful. The body of evidence relating to topical investigational agents is growing and involves controlled trials as well as individual cases. The largest single body of information is for topical ketamine, administered either alone or combined with other agents (particularly amitriptyline), and some large randomized controlled trials report efficacy. Other large trials involve topical clonidine and further ketamine combinations. Compounding analgesics involves challenges, including uncertain composition (two to five ingredients are used) and concentrations (range 0.5–5 %), as well as the heterogeneity of data that support choices. Nevertheless, case reports and acceptable response rates in larger cohorts are intriguing, and this area merits further investigation in controlled settings as well as continued documentation of clinical experiences.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Treede RD, Jensen TS, Campbell JN, et al. Neuropathic pain. Redefinition and a grading system for clinical and research purposes. Neurology. 2008;70(18):1630–5.

    Article  CAS  PubMed  Google Scholar 

  2. Baron R. Mechanisms of disease: neuropathic pain—a clinical perspective. Nat Clin Pract Neurol. 2006;2(2):95–106.

    Article  PubMed  Google Scholar 

  3. Baron R, Binder A, Wasner G. Neuropathic pain: diagnosis, pathophysiological mechanisms, and treatment. Lancet Neurol. 2010;9(8):807–19.

    Article  PubMed  Google Scholar 

  4. Von Hehn CA, Caron R, Woolf CJ. Deconstructing the neuropathic pain phenotype to reveal neural mechanisms. Neuron. 2012;73(4):638–52.

    Article  Google Scholar 

  5. Truini A, Garcia-Larrea L, Cruccu G. Reappraising neuropathic pain in humans—how symptoms help disclose mechanisms. Nat Neurol. 2013;9(10):572–82.

    Article  CAS  Google Scholar 

  6. Barkin RL. The pharmacology of topical analgesics. Postgrad Med. 2013;125(4 suppl 1):7–18.

    PubMed  Google Scholar 

  7. Argoff CE. Topical analgesics in the management of acute and chronic pain. Mayo Clin Proc. 2013;88(2):195–205.

    Article  CAS  PubMed  Google Scholar 

  8. Hochberg MC, Altman RD, April KT, et al. American College of Rheumatology 2012 Recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip and knee. Arthritis Care Res. 2012;64(4):465–74.

    Article  CAS  Google Scholar 

  9. Balmaceda CM. Evolving guidelines in the use of topical nonsteroidal anti-inflammatory drugs in the treatment of osteoarthritis. BMC Musculoskeletal Disord. 2014; 15:27 (5 pages).

  10. Argoff CE, Gloth FM. Topical nonsteroidal anti-inflammatory drugs for management of osteoarthritis in long-term care patients. Ther Clin Risk Manag. 2011;7:393–9.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  11. Peniston JH, Gold MS, Wieman MS, et al. Long-term tolerability of topical diclofenac sodium 1 % gel for osteoarthritis in seniors and patients with comorbidities. Clin Interv Aging. 2012;7:517–23.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  12. Sawynok J. Topical analgesics for neuropathic pain: preclinical exploration, clinical validation, future development. Eur J Pain. 2014;18(4):465–81.

    Article  CAS  PubMed  Google Scholar 

  13. Zur E. Topical treatment of neuropathic pain using compounded medications. Clin J Pain. 2014;30(1):73–91.

    Article  PubMed  Google Scholar 

  14. Van Hecke O, Austin SK, Khan RA, et al. Neuropathic pain in the general population: a systematic review of epidemiological studies. Pain. 2014;155(4):654–62.

    Article  PubMed  Google Scholar 

  15. Smith BH, Torrance N. Epidemiology of neuropathic pain and its impact on quality of life. Curr Pain Headache Rep. 2012;16(3):191–8.

    Article  PubMed  Google Scholar 

  16. Torrance N, Smith BH, Bennett MI, et al. The epidemiology of chronic pain of predominantly neuropathic origin. Results from a general population survey. J Pain. 2006;7(4):281–9.

    Article  PubMed  Google Scholar 

  17. Gore M, Dukes E, Rowbotham DJ, et al. Clinical characteristics and pain management among patients with painful peripheral neuropathic disorders in general practice settings. Eur J Pain. 2007;11(6):652–64.

    Article  PubMed  Google Scholar 

  18. Bouhassira D, Lantéri-Minet M, Attal N, et al. Prevalence of chronic pain with neuropathic characteristics in the general population. Pain. 2008;136(3):380–7.

    Article  PubMed  Google Scholar 

  19. Gajria C, Murray J, Birger R, et al. Identification of patients with neuropathic pain using electronic primary care records. Inform Prim Care. 2011;19(2):83–90.

    PubMed  Google Scholar 

  20. De Moraes Vieira EB, Santos Garcia JB, Moura da Silva AA, et al. Prevalence, characteristics, and factors associated with chronic pain with and without neuropathic characteristics in São Luís, Brazil. J Pain Symptom Manag. 2012;44(2):239–51.

    Article  Google Scholar 

  21. Jensen MP, Chodroff MJ, Dworkin RH. The impact of neuropathic pain on health-related quality of life: review and implications. Neurology. 2007;68(15):1178–82.

    Article  PubMed  Google Scholar 

  22. O’Connor AB. Neuropathic pain: a review of the quality-of-life impact, costs, and cost effectiveness of therapy. Pharmacoeconomics. 2009;27(2):95–112.

    Article  PubMed  Google Scholar 

  23. Dworkin RH, Malone DC, Panarites CJ, et al. Impact of postherpetic neuralgia and painful diabetic peripheral neuropathy on health care costs. J Pain. 2010;11(4):360–8.

    Article  PubMed  Google Scholar 

  24. Hall GC, Carroll D, Parry D, et al. Epidemiology and treatment of neuropathic pain: the UK primary care perspective. Pain. 2006;122(1–2):156–62.

    Article  PubMed  Google Scholar 

  25. Dieleman JP, Kerklaan J, Huygen FJ, et al. Incidence rates and treatment of neuropathic pain conditions in the general population. Pain. 2008;137(3):681–8.

    Article  PubMed  Google Scholar 

  26. Koopman JS, Dieleman JP, Huygen FJ, et al. Incidence of facial pain in the general population. Pain. 2009;147(1–3):122–7.

    Article  PubMed  Google Scholar 

  27. Ji JS, Chen YJ, Lin MW, et al. Epidemiological features and costs of herpes zoster in Taiwan: a national study 2000 to 2006. Acta Derm Venereol. 2009;89(6):612–6.

    Article  Google Scholar 

  28. Pierik JG, Gumbs PD, Fortanier SA, et al. Epidemiological characteristics and societal burden of varicella zoster virus in the Netherlands. BMC Infect Dis. 2012; 12:110.

  29. American Geriatrics Society Panel. Pharmacological management of persistent pain in older persons. Pain Med. 2009;10(6):1062–83.

    Article  Google Scholar 

  30. Bruckenthal P, Reid MC, Reisner L. Special issues in the management of chronic pain in older adults. Pain Med. 2009;10(S2):S67–78.

    Article  PubMed  Google Scholar 

  31. Fine PG. Treatment guidelines for the pharmacological management of pain in older persons. Pain Med. 2012;13(Suppl 2):S57–66.

    Article  PubMed  Google Scholar 

  32. Abdulla A, Adams N, Bone M, et al. Guidance on the management of pain in older people. Age Aging. 2013;42(2):i1–57.

    Article  Google Scholar 

  33. Attal N, Cruccu G, Baron R, et al. EFNS Guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol. 2010;17(9):1113–23.

    Article  CAS  PubMed  Google Scholar 

  34. Dworkin RH, O’Conner AB, Audette J, et al. Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. Mayo Clin Proc. 2010;85(Suppl 3):S3–14.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  35. Finnerup NB, Sindrup SH, Jensen TS. The evidence for pharmacological treatment of neuropathic pain. Pain. 2010;150(3):573–81.

    Article  PubMed  Google Scholar 

  36. Magrinelli F, Zanette G, Tamburin S. Neuropathic pain: diagnosis and treatment. Pract Neurol. 2013;13(5):292–307.

    Article  PubMed  Google Scholar 

  37. Snedecor SJ, Sudharshan L, Cappelleri JC, et al. Systematic review and meta-analysis of pharmacological therapies for pain associated with postherpetic neuralgia and less common neuropathic conditions. Int J Clin Pract. 2014;68(7):900–18.

    Article  CAS  PubMed  Google Scholar 

  38. Snedecor SJ, Sudharshan L, Cappelleri JC, et al. Systematic review and meta-analysis of pharmacological therapies for painful diabetic peripheral neuropathy. Pain Pract. 2014;14(2):167–84.

    Article  PubMed  Google Scholar 

  39. Crucca G, Gronseth G, Alksne J, et al. AAN-EFNS guidelines on trigeminal neuralgia management. Eur J Neurol. 2008;71(15):1183–90.

    Google Scholar 

  40. Zakrzewska JM. Medical management of trigeminal neuropathic pains. Expert Opin Pharmacother. 2010;11(8):1239–54.

    Article  CAS  PubMed  Google Scholar 

  41. Schmader KE, Baron R, Haanpää ML, et al. Treatment considerations for elderly and frail patients with neuropathic pain. Mayo Clin Proc. 2010;83(3 suppl):S26–32.

    Article  Google Scholar 

  42. Haanpää ML, Gourlay GK, Kent JL, et al. Treatment considerations for patients with neuropathic pain and other medical comorbidities. Mayo Clin Proc. 2010;85(3 suppl):S15–25.

    Article  PubMed Central  PubMed  Google Scholar 

  43. O’Connor AB, Dworkin RH. Treatment of neuropathic pain: an overview of recent guidelines. Am J Med. 2009;122(10 Suppl):S22–32.

    Article  PubMed  Google Scholar 

  44. Chaparro LE, Wiffen PJ, Moore RA, et al. Combination pharmacotherapy for the treatment of neuropathic pain in adults. Cochrane Database Syst Rev. 2012; (7):CD008943.

  45. Gilron I, Jensen TS, Dickenson AH. Combination pharmacotherapy for management of chronic pain: from bench to bedside. Lancet Neurol. 2013;12(11):1084–95.

    Article  CAS  PubMed  Google Scholar 

  46. Tesfaye S, Wilhelm S, Lledo A, et al. Duloxetine and pregabalin: high-dose monotherapy or their combination? The COMBO-DN study—a multinational, randomized, double-blind, parallel-group study in patients with diabetic peripheral neuropathic pain. Pain. 2013;154(12):2616–25.

    Article  CAS  PubMed  Google Scholar 

  47. Davies PS, Galer BS. Review of lidocaine patch 5 % studies in the treatment of postherpetic neuralgia. Drugs. 2004;64(9):937–47.

    Article  CAS  PubMed  Google Scholar 

  48. Garnock-Jones KP, Keating GM. Lidocaine 5 % medicated plaster. A review of use in postherpetic neuralgia. Drugs. 2009;69(15):2149–65.

    Article  CAS  PubMed  Google Scholar 

  49. Mick G, Correa-Illanes G. Topical pain management with the 5 % lidocaine medicated plaster—a review. Curr Med Res Opin. 2012;28(6):937–51.

    Article  CAS  PubMed  Google Scholar 

  50. Correa-Illanes G, Rao R, Pineros JL, et al. Use of 5 % lidocaine medicated plaster to treat localized neuropathic pain secondary to traumatic injury of peripheral nerves. Local Reg Anesth. 2012;5:47–53.

    CAS  PubMed Central  PubMed  Google Scholar 

  51. Likar R, Kager I, Obmann M, et al. Treatment of localized neuropathic pain after disk herniation with 5 % lidocaine medicated plaster. Int J Gen Med. 2012;5:689–92.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  52. Galer BS, Jensen MP, Ma T, et al. The lidocaine patch 5 % effectively treats all neuropathic pain qualities: results of a randomized, double-blind, vehicle-controlled, 3-week efficacy study with use of the neuropathic pain scale. Clin J Pain. 2002;18(5):297–301.

    Article  PubMed  Google Scholar 

  53. Katz NP, Gammaitoni AR, Davis MW, Lidoderm Patch Study Group, et al. Lidocaine patch 5 % reduces pain intensity and interference with quality of life in patients with postherpetic neuralgia: an effectiveness trial. Pain Med. 2002;3(4):324–32.

    Article  PubMed  Google Scholar 

  54. Binder A, Bruxelle J, Rogers P, et al. Topical 5 % lidocaine (lignocaine) medicated plaster treatment for post-herpetic neuralgia. Results of a double-blind, placebo-controlled, multinational efficacy and safety trial. Clin Drug Res. 2009;29(6):393–408.

    CAS  Google Scholar 

  55. Baron R, Mayoral V, Leijon G, et al. 5 % Lidocaine medicated plaster versus pregabalin in post-herpetic neuralgia and diabetic polyneuropathy: an open-label, non-inferiority two-stage RCT study. Curr Med Res Opin. 2009;25(7):1663–76.

    Article  CAS  PubMed  Google Scholar 

  56. Mick G, Baron R, Finnerup NB, et al. What is localized neuropathic pain? A first proposal to characterize and define a widely used term. Pain Manag. 2012;2(1):71–7.

    Article  PubMed  Google Scholar 

  57. Kern KU, Nalamachu S, Brasseur L, et al. Can treatment success with 5 % lidocaine medicated plaster be predicted in cancer pain with neuropathic components or trigeminal neuropathic pain? J Pain Res. 2013;6:261–80.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  58. Casale R, Mattia C. Building a diagnostic algorithm on localized neuropathic pain (LNP) and targeted topical treatment: focus on 5 % lidocaine-medicated plaster. Ther Clin Risk Manag. 2014;10:259–68.

    Article  PubMed Central  PubMed  Google Scholar 

  59. Nalamachu S, Wieman M, Bednarek L, et al. Influence of anatomic location of lidocaine patch 5 % on effectiveness and tolerability for postherpetic neuralgia. Patient Prefer Adherence. 2013;7:551–7.

    PubMed Central  PubMed  Google Scholar 

  60. Wilhelm IR, Tzabazis A, Likar R, et al. Long-term treatment of neuropathic pain with a 5 % lidocaine medicated plaster. Eur J Anaesthesiol. 2010;27(2):169–73.

    Article  CAS  PubMed  Google Scholar 

  61. Sabatowski R, Hans G, Tacken I, et al. Safety and efficacy outcomes of long-term treatment up to 4 years with 5 % lidocaine medicated plaster in patients with post-herpetic neuralgia. Curr Med Res Opin. 2012;28(8):1337–46.

    Article  CAS  PubMed  Google Scholar 

  62. Wolff RF, Bala MM, Westwood M, et al. 5 % lidocaine-medicated plaster vs other relevant interventions and placebo for post-herpetic neuralgia (PHN): a systematic review. Acta Neurol Scand. 2011;123(5):295–309.

    Article  CAS  PubMed  Google Scholar 

  63. Liedegens H, Obradovic M, Nuijten M. Health economic evidence of 5 % lidocaine medicated plaster in post-herpetic neuralgia. Clinicoecon Outcomes Res. 2013;5:597–609.

    Article  Google Scholar 

  64. Woulff RF, Bala MM, Westwood M, et al. 5 % lidocaine medicated plaster in painful diabetic peripheral neuropathy (DPN): a systematic review. Swiss Med Wkly. 2010;140(21–22):297–306.

    Google Scholar 

  65. Clère F, Delorme-Morin C, George B, et al. 5 % lidocaine medicated plaster in elderly patients with postherpetic neuralgia. Results of a compassionate use programme in France. Drugs Aging. 2011;28(9):693–702.

    Article  PubMed  Google Scholar 

  66. Delorme C, Navez ML, Legout V, et al. Treatment of neuropathic pain with 5 % lidocaine-medicated plaster: five years of clinical experience. Pain Res Manag. 2011;16(4):259–63.

    PubMed Central  PubMed  Google Scholar 

  67. Pickering G, Pereira B, Clère F, et al. Cognitive function in older patients with postherpetic neuralgia. Pain Pract. 2014;14(1):E1–7.

    Article  PubMed  Google Scholar 

  68. Baron R, Mayoral V, Leijon G, et al. Efficacy and safety of combination therapy with 5 % lidocaine medicated plaster and pregabalin in post-herpetic neuralgia and diabetic neuropathy. Curr Med Res Opin. 2009;25(7):1677–87.

    Article  CAS  PubMed  Google Scholar 

  69. Anand P, Bley K. Topical capsaicin for pain management: therapeutic potential and mechanisms of action of the new high-concentration capsaicin 8 % patch. Br J Anaesth. 2011;107(4):490–502.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  70. Haanpää M, Treede RD. Capsaicin for neuropathic pain: linking traditional medicine and molecular biology. Eur Neurol. 2012;68(5):264–75.

    Article  PubMed  Google Scholar 

  71. Derry S, Moore RA. Topical capsaicin (low concentration) for chronic neuropathic pain in adults. Cochrane Database Syst Rev. 2012 (9):CD010111. doi:10.1002/14651858.CD010111.

  72. Baranidharan G, Das S, Bhaskar A. A review of the high-concentration capsaicin patch and experience of its use in the management of neuropathic pain. Ther Adv Neurol Disord. 2013;6(5):287–97.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  73. Backonja M, Wallace MS, Blonsky ER, et al. NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia: a randomized, double-blind study. Lancet Neurol. 2008;7(12):1106–12.

    Article  CAS  PubMed  Google Scholar 

  74. Backonja M, Malan TP, Vanouve GF, et al. NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia: a randomized, double-blind, controlled study with an open-label extension. Pain Med. 2010;11(4):600–8.

    Article  PubMed  Google Scholar 

  75. Webster LR, Malan TP, Tuchman MM, et al. A multicenter, randomized, double-blind, controlled dose finding study of NGX-4010, a high-concentration capsaicin patch for the treatment of postherpetic neuralgia. J Pain. 2010;11(10):972–82.

    Article  CAS  PubMed  Google Scholar 

  76. Irving GA, Backonjka MM, Dunteman E, et al. A multicenter, randomized, double-blind, controlled study of NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia. Pain Med. 2011;12(1):99–109.

    Article  PubMed  Google Scholar 

  77. Mou J, Paillard F, Turnbull B, et al. Efficacy of Qutenza® (capsaicin) 8 % patch for neuropathic pain: a meta-analysis of the Qutenza Clinical Trials database. Pain. 2013;154(9):1632–9.

    Article  CAS  PubMed  Google Scholar 

  78. Mou J, Paillard F, Turnbull B, et al. Qutenza (capsaicin) 8 % patch onset and duration of response and effects of multiple treatments in neuropathic pain patients. Clin J Pain. 2014;30(4):286–94.

    Article  PubMed  Google Scholar 

  79. Peppin JF, Majors K, Webster LR, et al. Tolerability of NGX-4010, a capsaicin 8 % patch for peripheral neuropathic pain. J Pain Res. 2011;4:385–92.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  80. Treede RD, Wagner T, Kern KU, et al. Mechanism- and experience-based strategies to optimize treatment response to the capsaicin 8 % cutaneous patch in patients with localized neuropathic pain. Curr Med Res Opin. 2013;29(5):527–38.

    Article  CAS  PubMed  Google Scholar 

  81. Wagner T, Poole C, Roth-Daniek A. The capsaicin 8 % patch for neuropathic pain in clinical practice: a retrospective analysis. Pain Med. 2013;14(8):1202–11.

    Article  PubMed Central  PubMed  Google Scholar 

  82. Wagner T, Roth-Daniek A, Sell A, et al. Capsaicin 8 % patch for peripheral neuropathic pain: review of treatment best practice from “real-world” clinical experience. Pain Manag. 2012;2(3):239–50.

    Article  PubMed  Google Scholar 

  83. Kern KU, Nowak W, Poole C. Treatment of neuropathic pain with the capsaicin 8 % patch: is pretreatment with lidocaine necessary? Pain Pract. 2014;14(2):E42–50.

    Article  PubMed  Google Scholar 

  84. Kern KU, England J, Roth-Daniek A, et al. Is physician supervision of the capsaicin 8 % patch administration procedure really necessary? An opinion from health care professionals. J Pain Res. 2013;6:571–5.

    Article  PubMed Central  PubMed  Google Scholar 

  85. Armstrong EP, Malone DC, McCarberg B, et al. Cost-effectiveness analysis of a new 8 % capsaicin patch compared to existing therapies for postherpetic neuralgia. Curr Med Res Opin. 2011;27(5):939–50.

    Article  PubMed  Google Scholar 

  86. Irving GA, Backonja M, Rauck R, et al. NGX-4010, a capsaicin 8 % dermal patch, administered alone or in combination with systemic neuropathic pain medications, reduces pain in patients with postherpetic neuralgia. Clin J Pain. 2012;28(8):101–7.

    Article  PubMed  Google Scholar 

  87. Sawynok J. Topical and peripheral ketamine as an analgesic. Anesth Analg. 2014;119(1):170–8.

    Article  CAS  PubMed  Google Scholar 

  88. Kopsky DJ, Keppel Hesselink JM, Bhaskar A, et al. Analgesic effects of topical Ketamine. Minerva Anesthesiol. 2014 [ePub ahead of print].

  89. Barton DL, Wos EJ, Qin R, et al. A double-blind, placebo-controlled trial of a topical treatment for chemotherapy-induced peripheral neuropathy: NCCTG trial N06CA. Support Care Cancer. 2011;19(6):833–41.

    Article  PubMed Central  PubMed  Google Scholar 

  90. Campbell CM, Kipnes MS, Stouch BC, et al. Randomized control trial of topical clonidine for treatment of painful diabetic neuropathy. Pain. 2012;153(9):1815–23.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  91. Gewandter JS, Mobile SG, Heckler CE, et al. A phase III randomized, placebo-controlled study of topical amitriptyline and ketamine for chemotherapy-induced peripheral neuropathy (CIPN): a University of Rochester CCOP study of 462 cancer survivors. Support Care Cancer. 2014;22(7):1807–14.

    Article  PubMed Central  PubMed  Google Scholar 

  92. NCT00475904 http://www.clinicaltrials.gov.

  93. NCT00476151 http://www.clinicaltrials.gov.

  94. Heir G, Karolchek S, Kalladka M, et al. Use of topical medication in orofacial neuropathic pain: a retrospective study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2008;105(4):466–9.

    Article  PubMed  Google Scholar 

  95. Poterucha TJ, Murphy SL, Rho RH, et al. Topical amitriptyline-ketamine for treatment of rectal, genital, and perineal pain and discomfort. Pain Phys. 2012;15(6):485–8.

    Google Scholar 

  96. Poterucha TJ, Murphy SL, Rho RH, et al. Topical amitriptyline combined with topical ketamine for the management of recalcitrant localized pruritis: a retrospective pilot study. J Am Acad Dermatol. 2013;69(2):320–1.

    Article  CAS  PubMed  Google Scholar 

  97. Poterucha TJ, Murphy SL, Davis MDP, et al. Topical amitriptyline combined with ketamine for the treatment of erythromelalgia: a retrospective study of 36 patients at Mayo Clinic. J Drugs Dermatol. 2013;12(3):308–10.

    CAS  PubMed  Google Scholar 

  98. Tam E, Furlan AD. Transdermal lidocaine and ketamine for neuropathic pain: a study of effectiveness and tolerability. Open Neurol J. 2012;6:58–64.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  99. Nasri-Heir C, Khan J, Heir GM. Topical medications as treatment of neuropathic orofacial pain. Dent Clin N Am. 2013;57(3):541–53.

    Article  PubMed  Google Scholar 

  100. Lynch ME, Clark AJ, Sawynok J, Sullivan MJL. Topical 2 % amitriptyline and 1 % ketamine in neuropathic pain syndromes. A randomized, double-blind, placebo-controlled trial. Anesthesiology. 2005;103(1):140–6.

    Article  CAS  PubMed  Google Scholar 

  101. Mahoney JM, Vardaxis V, Moore JL, et al. Topical ketamine cream in the treatment of painful diabetic neuropathy. A randomized, placebo-controlled, double-blind initial study. J Am Podiatr Med Assoc. 2012;102(3):178–83.

    Article  PubMed  Google Scholar 

  102. De Barros GAM, Miot HA, Braz AM, et al. Topical (S)-ketamine for pain management of postherpetic neuralgia. An Bras Dermatol. 2012;87(3):504–6.

    Article  PubMed  Google Scholar 

  103. Finch PM, Knudsen L, Drummond PD. Reduction of allodynia in patients with complex regional pain syndrome: a double-blind placebo-controlled trial of topical ketamine. Pain. 2009;146(1–2):18–25.

    Article  CAS  PubMed  Google Scholar 

  104. Lockhart E. Topical combination of amitriptyline and ketamine for post-herpetic neuralgia. J Pain. 2004;5:S82.

    Article  Google Scholar 

  105. Rowbotham MC, Gilron I, Glazer C, et al. Can pragmatic trials help us better understand chronic pain and improve treatment? Pain. 2013;154(5):643–6.

    Article  PubMed  Google Scholar 

  106. Kalso E, Aldington DJ, Moore RA. Drugs for neuropathic pain. BMJ. 2013;347:f7339.

    Article  PubMed  Google Scholar 

  107. Moore A, Derry S, Eccelston C, et al. Expect analgesic failure; pursue analgesic success. BMJ. 2013;346:f2690.

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

No sources of funding were used to support the preparation of this article.

Disclaimer

The author has received license fees from EpiCept (now Immune Pharmaceuticals Inc.).

Author information

Authors and Affiliations

  1. Department of Pharmacology, Dalhousie University, Halifax, NS, B3H 4R2, Canada

    Jana Sawynok

Authors
  1. Jana Sawynok
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jana Sawynok.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sawynok, J. Topical Analgesics for Neuropathic Pain in the Elderly: Current and Future Prospects. Drugs Aging 31, 853–862 (2014). https://doi.org/10.1007/s40266-014-0218-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40266-014-0218-9

Keywords

Search

Navigation